BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 17467883)

  • 1. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
    J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
    D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
    J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
    J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term mortality with localized prostate cancer.
    Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
    Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy--long-term oncological outcome from a community hospital.
    Tol-Fakkar M; Hermansson CG; Hugosson J; Pedersen K; Aus G
    Scand J Urol Nephrol; 2003; 37(5):376-81. PubMed ID: 14594684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we treat localized prostate cancer? An opinion.
    Menon M; Parulkar BG; Baker S
    Urology; 1995 Nov; 46(5):607-16. PubMed ID: 7495109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of watchful waiting for clinically localized prostate cancer.
    Steinberg GD; Bales GT; Brendler CB
    J Urol; 1998 May; 159(5):1431-6. PubMed ID: 9554328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
    Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
    J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    Cancer; 2003 Jan; 97(1):56-62. PubMed ID: 12491505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.